Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have earned a consensus rating of “Buy” from the ten brokerages that are covering the stock, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $111.78.
VKTX has been the topic of a number of recent analyst reports. Raymond James increased their price objective on Viking Therapeutics from $116.00 to $118.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 25th. StockNews.com upgraded Viking Therapeutics to a “sell” rating in a research report on Wednesday, July 31st. HC Wainwright restated a “buy” rating and issued a $90.00 price objective on shares of Viking Therapeutics in a research report on Thursday, July 25th. Maxim Group reaffirmed a “buy” rating and issued a $120.00 target price on shares of Viking Therapeutics in a research note on Tuesday, June 4th. Finally, Morgan Stanley started coverage on shares of Viking Therapeutics in a research note on Thursday, June 27th. They issued an “overweight” rating and a $105.00 price target for the company.
Get Our Latest Analysis on VKTX
Insider Activity
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the business. Avoro Capital Advisors LLC bought a new position in Viking Therapeutics in the 1st quarter worth $294,380,000. Vanguard Group Inc. raised its stake in Viking Therapeutics by 44.7% in the first quarter. Vanguard Group Inc. now owns 7,785,724 shares of the biotechnology company’s stock worth $638,429,000 after buying an additional 2,403,820 shares in the last quarter. Perpetual Ltd purchased a new stake in Viking Therapeutics in the first quarter worth about $78,586,000. Hood River Capital Management LLC bought a new stake in Viking Therapeutics during the 1st quarter valued at approximately $55,098,000. Finally, Massachusetts Financial Services Co. MA purchased a new position in shares of Viking Therapeutics during the 4th quarter worth approximately $12,341,000. Hedge funds and other institutional investors own 76.03% of the company’s stock.
Viking Therapeutics Trading Down 2.3 %
Viking Therapeutics stock opened at $54.13 on Wednesday. The firm has a market capitalization of $6.00 billion, a price-to-earnings ratio of -58.20 and a beta of 1.00. Viking Therapeutics has a 1-year low of $8.28 and a 1-year high of $99.41. The firm has a 50 day simple moving average of $57.18 and a 200 day simple moving average of $63.26.
Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last announced its quarterly earnings results on Wednesday, July 24th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.06. During the same quarter in the previous year, the company earned ($0.19) earnings per share. On average, equities research analysts forecast that Viking Therapeutics will post -0.99 EPS for the current year.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
See Also
- Five stocks we like better than Viking Therapeutics
- How to Use the MarketBeat Stock Screener
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- How to Capture the Benefits of Dividend Increases
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- Industrial Products Stocks Investing
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.